Post-marketing surveillance of administration of botulinum toxin type B(NerBloc )-Investigation of the clinical condition and safety in patients with cervical dystonia (Study NB01S)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2018
Price : $35 *
At a glance
- Drugs Botulinum toxin B (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 27 Aug 2018 Planned number of patients changed from 150 to 1647.
- 27 Aug 2018 Planned End Date changed from 31 Aug 2019 to 30 Jun 2019.
- 27 Aug 2018 Planned primary completion date changed from 31 Jan 2019 to 30 Jun 2019.